Skip to main content

Tapentadol News

FDA Medwatch Alert: Opioid Pain or Cough Medicines Combined With Benzodiazepines: Drug Safety Communication - FDA Requiring New Boxed Warnings About Serious Risks and Death

ISSUE: FDA review has found that the growing combined use of opioid medicines with benzodiazepines or other drugs that depress the central nervous system (CNS) has resulted in serious side effects,...

FDA Medwatch Alert: Opioid Pain Medicines: Drug Safety Communication - New Safety Warnings Added to Prescription Opioid Medications

ISSUE: FDA is warning about several safety issues with the entire class of opioid pain medicines. See the FDA Drug Safety Communication for a complete listing. These safety risks are potentially h...

FDA Approves Nucynta ER (tapentadol) Extended-Release Oral Tablets for the Management of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy

RARITAN, N.J., Aug. 29, 2012 /PRNewswire/ – Janssen Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for...

Nucynta ER (Tapentadol Extended-Release Tablets) Receives FDA Approval for the Management of Moderate to Severe Chronic Pain

Raritan, N.J., August 26, 2011 /PRNewswire/ — Janssen Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration (FDA) has approved Nucynta ER, an oral analgesic taken twice daily, f...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related condition support groups

Diabetic Neuropathy, Diabetic Nerve Damage, Pain

Related drug support groups

Nucynta

Tapentadol patient information at Drugs.com